• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Chemomab Therapeutics Ltd. - American Depositary Shares (NQ:CMMB)

    1.659 +0.019 (+1.13%)
    Streaming Delayed Price Updated: 12:05 PM EST, Dec 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 61,706
    Open 1.640
    Bid (Size) 1.620 (100)
    Ask (Size) 1.690 (200)
    Prev. Close 1.640
    Today's Range 1.600 - 1.690
    52wk Range 1.599 - 9.840
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
    From Chemomab Therapeutics Ltd.
    Via GlobeNewswire
    News headline image
    Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
    From Chemomab Therapeutics Ltd.
    Via GlobeNewswire

    Performance

    YTD
    -80.5%
    -80.5%
    1 Month
    -36.7%
    -36.7%
    3 Month
    -36.9%
    -36.9%
    6 Month
    -64.3%
    -64.3%
    1 Year
    -79.5%
    -79.5%

    More News

    Read More
    News headline image
    Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Announces New Medical and Clinical Appointments
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease ↗
    Via Benzinga
    News headline image
    Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
    From Chemomab Therapeutics
    Via GlobeNewswire
    News headline image
    Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
    From Chemomab Therapeutics
    Via GlobeNewswire

    Frequently Asked Questions

    Is Chemomab Therapeutics Ltd. - American Depositary Shares publicly traded?
    Yes, Chemomab Therapeutics Ltd. - American Depositary Shares is publicly traded.
    What exchange does Chemomab Therapeutics Ltd. - American Depositary Shares trade on?
    Chemomab Therapeutics Ltd. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares?
    The ticker symbol for Chemomab Therapeutics Ltd. - American Depositary Shares is CMMB on the Nasdaq Stock Market
    What is the current price of Chemomab Therapeutics Ltd. - American Depositary Shares?
    The current price of Chemomab Therapeutics Ltd. - American Depositary Shares is 1.659
    When was Chemomab Therapeutics Ltd. - American Depositary Shares last traded?
    The last trade of Chemomab Therapeutics Ltd. - American Depositary Shares was at 12/31/25 12:05 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.